$55.45
Value $2.8B
ATRC and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$55.45
Value $2.8B
$272.70
Value $657B
AtriCure (ATRC) has a market value of $2.8B and Johnson & Johnson (JNJ) $657B. Over the last year, with dividends, ATRC moved +67.4% and JNJ +39.7%. The P/E is 185.6 for ATRC and 40.8 for JNJ. Dividend yield: ATRC none, JNJ 1.94%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ATRC$2.8B
JNJ$657B
JNJ is 238 times ATRC
Revenue, 12 months
ATRC$590M
JNJ$99.3B
JNJ is 168 times ATRC
Net income, 12 months
ATRC$15M
JNJ$16.1B
JNJ is 1,081 times ATRC
Operating margin
ATRC2.9%
JNJ–
ROIC
ATRC2.8%
JNJ12.4%
9.6 points apart
P/E
ATRC185.6
JNJ40.8
ATRC is 4.5 times JNJ
Dividend yield
ATRC0.0%
JNJ1.9%
1.9 points apart
5-year return
ATRC-29.2%
JNJ+92.0%
121.2 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ATRC-29.2%
JNJ+92.0%
| Period | ATRCWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +67.4%Price +67.4% | +39.7%Price +36.6% |
| 3 years since November 17, 2023 | +33.6%+10.1% a yearPrice +33.6% | +98.2%+25.6% a yearPrice +82.1% |
| 5 years since November 17, 2021 | -29.2%-6.7% a yearPrice -29.2% | +92.0%+13.9% a yearPrice +67.0% |
| 10 years since November 21, 2016 | +183.2%+11.0% a yearPrice +183.2% | +209.0%+11.9% a yearPrice +137.1% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ATRCAtriCureJNJJohnson & Johnson
| Price | $55.45 | $272.70 |
|---|---|---|
| Market value | $2.8B | $657B |
| Enterprise value (EV) | $2.7B | $685B |
| P/E | 185.6 | 40.8 |
| P/E, 5-year median | – | 21.9 |
| P/B | 5.2 | 8.1 |
| EV/EBIT | 156.5 | 38.6 |
| Free cash flow yield | 1.9% | 3.1% |
| Revenue, 12 months | $590M | $99.3B |
|---|---|---|
| Net income, 12 months | $15M | $16.1B |
| Free cash flow, 12 months | $53M | $20.6B |
| Earnings per share, 12 months | $0.30 | $6.59 |
| Revenue growth, year on year | 14.9% | 6.1% |
| Revenue growth a year, past | +21.0%over 5 years | +2.7%over 5 years |
| EPS growth a year, past | – | +14.9%over 5 years |
| Gross margin | 76.7% | 67.6% |
|---|---|---|
| Operating margin | 2.9% | – |
| Net margin | 2.5% | 16.2% |
| ROIC | 2.8% | 12.4% |
| ROE | 3.0% | 19.7% |
| Cash | $187M | $17.2B |
|---|---|---|
| Total debt | $97M | $44.7B |
| Net debt / EBITDA | -3.3 | 1.1 |
| Interest cover | 3.0× | 18.0× |
| Dividend yield | – | 1.9% |
|---|---|---|
| Dividend per share, 12 months | – | $5.28 |
| Dividend growth a year, past | – | +5.3%over 5 years |
| Buyback yield | – | 0.9% |
| Shareholder yield | – | 2.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($657B) is about 237.9 times AtriCure ($2.8B), at today's prices.
Since November 21, 2016, ATRC's price moved +183.2% and JNJ's +137.1%. With dividends: ATRC +183.2% (+11.0% a year), JNJ +209.0% (+11.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for AtriCure and 1.94% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.
At today's price, the P/E is 185.6 for ATRC and 40.8 for JNJ. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 2.5% for AtriCure and 16.2% for Johnson & Johnson, and the operating margin 2.9% and –. Revenue was $590M and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.